Investigational drug · Phase 3
9MW2821
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
19
Any phase or sponsor naming "9MW2821"
First trial start
2023
Sep 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "9MW2821", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Urothelial Carcinoma
- Advanced Urothelial Carcinoma
- Locally Advanced or Metastatic Triple-negative Breast Cancer
- Gynecological Malignancies
- Solid Tumors
- Triple-Negative Breast Cancer
- Cervical Cancer
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Recurrent
- Urothelial Carcinoma of the Renal Pelvis and Ureter
Approved drugs for the same conditions: Breast cancer · Bladder and urothelial cancer · Cervical cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "9MW2821" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerPivotal-lookingRecruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06592326 · 460 participants (planned) · Start Aug 22, 2024 · Primary completion Sep 2027
Drug: 9MW2821; Toripalimab and 2 more · For: Urothelial Carcinoma
Sites: Shanghai, China
- A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerPivotal-lookingRecruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06196736 · 432 participants (planned) · Start Dec 29, 2023 · Primary completion Sep 2026
Drug: 9MW2821; Chemotherapy · For: Advanced Urothelial Carcinoma
Sites: Shanghai, China
- A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerPivotal-lookingRecruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06692166 · 420 participants (planned) · Start Sep 10, 2024 · Primary completion Dec 9, 2027
Drug: 9MW2821; Chemotherapy · For: Cervical Cancer
Sites: Beijing, China; Shanghai, China
- A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerPivotal-lookingNot yet recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT07556848 · 356 participants (planned) · Start May 2026 · Primary completion Dec 2027
Drug: 9MW2821; Chemotherapy · For: Locally Advanced or Metastatic Triple-negative Breast Cancer
Sites: Shanghai, China
- 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological TumorsNot yet recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06926998 · 260 participants (planned) · Start Apr 15, 2025 · Primary completion May 1, 2027
Drug: 9MW2821+other anticancer therapy · For: Gynecological Malignancies
Sites: Hangzhou, China
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT05216965 · 208 participants (planned) · Start Jun 11, 2022 · Primary completion Dec 2025
Drug: 9MW2821 · For: Solid Tumors
Sites: Shanghai, China
- A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsNot yet recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06947226 · 188 participants (planned) · Start Apr 2025 · Primary completion Apr 2026
Drug: 9MW2821; Other anti-cancer therapy · For: Solid Tumors
Sites: Zhengzhou, China
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT06649331 · 160 participants (planned) · Start Oct 21, 2024 · Primary completion Sep 2026
Drug: SHR-A1811; SHR-A1921 and 7 more · For: Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC) and 2 more
Sites: Shanghai, China
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerPivotal-lookingRecruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06492005 · 160 participants (planned) · Start Jul 26, 2024 · Primary completion Jul 2026
Drug: 9MW2821; PD-1 inhibitior · For: Triple-Negative Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them.
Yang C, Song X, Sun H, et al. · Front Immunol 2026
- Structural basis of nectin-4 recognition by the antibody-drug conjugate 9MW2821.
Fang P, You M, Wen H, et al. · J Biol Chem 2025
- Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.
Zhang J, Liu R, Wang S, et al. · Ann Oncol 2025
- Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate.
Fang P, You M, Cao Y, et al. · J Pharm Biomed Anal 2024
- Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W, Fang P, Yu D, et al. · Mol Cancer Ther 2023
Also in development for Urothelial Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- LivmoniplimabABBV-151Phase 34 trials
AbbVie · Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.